430 related articles for article (PubMed ID: 16984995)
21. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly.
Barkan AL; Halasz I; Dornfeld KJ; Jaffe CA; Friberg RD; Chandler WF; Sandler HM
J Clin Endocrinol Metab; 1997 Oct; 82(10):3187-91. PubMed ID: 9329336
[TBL] [Abstract][Full Text] [Related]
22. Clinical Characteristics and Management of Patients With McCune-Albright Syndrome With GH Excess and Precocious Puberty: A Case Series and Literature Review.
Zhai X; Duan L; Yao Y; Xing B; Deng K; Wang L; Feng F; Liang Z; You H; Yang H; Lu L; Chen S; Wang R; Pan H; Zhu H
Front Endocrinol (Lausanne); 2021; 12():672394. PubMed ID: 34777239
[TBL] [Abstract][Full Text] [Related]
23. The place of pegvisomant in the acromegaly treatment algorithm.
Paisley AN; Trainer PJ; Drake WM
Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S101-6. PubMed ID: 15135788
[TBL] [Abstract][Full Text] [Related]
24. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
25. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.
Herman-Bonert VS; Zib K; Scarlett JA; Melmed S
J Clin Endocrinol Metab; 2000 Aug; 85(8):2958-61. PubMed ID: 10946911
[TBL] [Abstract][Full Text] [Related]
26. Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.
Briet C; Ilie MD; Kuhn E; Maione L; Brailly-Tabard S; Salenave S; Cariou B; Chanson P
Endocrine; 2019 Feb; 63(2):348-360. PubMed ID: 30397873
[TBL] [Abstract][Full Text] [Related]
27. A boy with McCune-Albright syndrome associated with GH secreting pituitary microadenoma. Clinical findings and response to treatment.
Papadopoulou M; Doula S; Kitsios K; Kaltsas T; Kosta K
Hormones (Athens); 2006; 5(3):205-9. PubMed ID: 16950755
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
[TBL] [Abstract][Full Text] [Related]
29. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.
Parkinson C; Kassem M; Heickendorff L; Flyvbjerg A; Trainer PJ
J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148
[TBL] [Abstract][Full Text] [Related]
30. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly.
Jenkins PJ; Bates P; Carson MN; Stewart PM; Wass JA
J Clin Endocrinol Metab; 2006 Apr; 91(4):1239-45. PubMed ID: 16403824
[TBL] [Abstract][Full Text] [Related]
31. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients.
Madsen M; Poulsen PL; Orskov H; Møller N; Jørgensen JO
J Clin Endocrinol Metab; 2011 Aug; 96(8):2405-13. PubMed ID: 21632808
[TBL] [Abstract][Full Text] [Related]
32. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly.
Neggers SJ; van Aken MO; Janssen JA; Feelders RA; de Herder WW; van der Lely AJ
J Clin Endocrinol Metab; 2007 Dec; 92(12):4598-601. PubMed ID: 17895318
[TBL] [Abstract][Full Text] [Related]
33. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients.
Neggers SJ; de Herder WW; Feelders RA; van der Lely AJ
Pituitary; 2011 Sep; 14(3):253-8. PubMed ID: 21221818
[TBL] [Abstract][Full Text] [Related]
34. McCune-Albright syndrome: growth hormone and prolactin hypersecretion.
Christoforidis A; Maniadaki I; Stanhope R
J Pediatr Endocrinol Metab; 2006 May; 19 Suppl 2():623-5. PubMed ID: 16789626
[TBL] [Abstract][Full Text] [Related]
35. Acromegaly: a new therapy.
Friend KE
Cancer Control; 2002; 9(3):232-5. PubMed ID: 12090246
[TBL] [Abstract][Full Text] [Related]
36. The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs.
Colao A; Pivonello R; Cappabianca P; Auriemma RS; De Martino MC; Ciccarelli A; de Divitiis E; Lombardi G
J Endocrinol Invest; 2003; 26(10 Suppl):53-6. PubMed ID: 15497660
[TBL] [Abstract][Full Text] [Related]
37. Acromegaly with fibrous dysplasia: McCune-Albright Syndrome -- clinical studies in 3 cases and brief review of literature--.
Bhansali A; Sharma BS; Sreenivasulu P; Singh P; Vashisth RK; Dash RJ
Endocr J; 2003 Dec; 50(6):793-9. PubMed ID: 14709853
[TBL] [Abstract][Full Text] [Related]
38. Growth hormone hypersecretion in a girl with McCune-Albright syndrome: comparison with controls and response to a dose of long-acting somatostatin analog.
Feuillan PP; Jones J; Ross JL
J Clin Endocrinol Metab; 1995 Apr; 80(4):1357-60. PubMed ID: 7714111
[TBL] [Abstract][Full Text] [Related]
39. Growth hormone receptor antagonists.
van der Lely AJ; Kopchick JJ
Neuroendocrinology; 2006; 83(3-4):264-8. PubMed ID: 17047392
[TBL] [Abstract][Full Text] [Related]
40. Treatment of acromegaly.
Holdaway IM
Horm Res; 2004; 62 Suppl 3():79-92. PubMed ID: 15539805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
